The current stock price of LNTH is 66.69 USD. In the past month the price decreased by -0.46%. In the past year, price decreased by -15.97%.
ChartMill assigns a technical rating of 5 / 10 to LNTH. When comparing the yearly performance of all stocks, LNTH turns out to be only a medium performer in the overall market: it outperformed 53.52% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to LNTH. Both the health and profitability get an excellent rating, making LNTH a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months LNTH reported a non-GAAP Earnings per Share(EPS) of 5.96. The EPS decreased by -14.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.99% | ||
| ROA | 7.37% | ||
| ROE | 14.98% | ||
| Debt/Equity | 0.51 |
19 analysts have analysed LNTH and the average price target is 85.13 USD. This implies a price increase of 27.65% is expected in the next year compared to the current price of 66.69.
For the next year, analysts expect an EPS growth of -16.21% and a revenue growth -1.03% for LNTH
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 18.14 | 16.217B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.59 | 14.082B | ||
| SOLV | SOLVENTUM CORP | 12.52 | 13.956B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 19.68 | 4.875B | ||
| ICUI | ICU MEDICAL INC | 18.02 | 3.783B | ||
| XRAY | DENTSPLY SIRONA INC | 8.83 | 2.78B | ||
| HAE | HAEMONETICS CORP/MASS | 10.51 | 2.763B | ||
| NEOG | NEOGEN CORP | 31.51 | 2.332B | ||
| UFPT | UFP TECHNOLOGIES INC | 26.13 | 2.063B |
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 808 full-time employees. The company went IPO on 2015-06-25. The firm's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The firm's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The firm's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The firm's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
LANTHEUS HOLDINGS INC
331 Treble Cove Road
North Billerica MASSACHUSETTS 01862 US
CEO: Mary Anne Heino
Employees: 808
Phone: 19786718001
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 808 full-time employees. The company went IPO on 2015-06-25. The firm's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The firm's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The firm's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The firm's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
The current stock price of LNTH is 66.69 USD. The price decreased by -0.71% in the last trading session.
LNTH does not pay a dividend.
LNTH has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
LNTH stock is listed on the Nasdaq exchange.
The PE ratio for LANTHEUS HOLDINGS INC (LNTH) is 11.19. This is based on the reported non-GAAP earnings per share of 5.96 and the current share price of 66.69 USD.
LANTHEUS HOLDINGS INC (LNTH) will report earnings on 2026-02-19, after the market close.